Obsessive-compulsive disorder can consume hours of a person’s day. Intrusive thoughts may create intense fear, guilt, doubt, or disgust, while compulsions provide only temporary relief before the cycle begins again.
Exposure and response prevention therapy and serotonin reuptake inhibitors are established first-line treatments for OCD. They help many people regain time, independence, and confidence. However, not everyone achieves remission after an initial course of therapy or medication.
Some patients improve partially but continue to feel controlled by rituals or mental compulsions. Others struggle to access an ERP-trained therapist, cannot tolerate medication side effects, or discover that an earlier treatment trial was not structured specifically for OCD.
At Thrive Center for Health in Grand Rapids, we work with patients whose symptoms have remained disruptive despite previous care. We begin by understanding what has already been tried and whether it represented an adequate OCD treatment. From there, we can discuss medication management, coordination with an OCD therapist, and whether an evaluation for ketamine therapy is reasonable.
Understanding the Cycle of Obsessions and Compulsions
OCD involves obsessions, compulsions, or both.
Obsessions are recurring thoughts, images, or urges that feel intrusive and unwanted. They may center on contamination, accidental harm, morality, religion, sexuality, relationships, order, illness, or the fear of making an irreversible mistake.
Compulsions are behaviors or mental acts performed in response to an obsession. They may include washing, checking, counting, arranging, repeating words, reviewing memories, seeking reassurance, confessing, avoiding triggers, or silently trying to neutralize a thought.
The compulsion may reduce anxiety briefly, but that relief reinforces the cycle. The brain learns that the ritual was necessary to prevent danger or resolve uncertainty, making the next obsession more difficult to tolerate without repeating the response.
Not every compulsion is visible. Someone may appear calm while mentally reviewing a conversation, repeating a phrase, testing their emotional response, or trying to prove that an intrusive thought does not reflect who they are.
Our discussion of OCD counting and repetitive rituals provides one example of how compulsions can become woven into everyday routines.
Why ERP Remains a Central OCD Treatment
Exposure and response prevention, commonly called ERP, is a specialized form of cognitive behavioral therapy.
During ERP, a patient gradually encounters thoughts, objects, situations, or sensations that trigger obsessions while practicing not performing the usual compulsion. The goal is not to prove that the feared outcome is impossible or force anxiety to disappear immediately. It is to help the person learn that uncertainty and discomfort can be tolerated without relying on a ritual.
ERP is often organized through a hierarchy that begins with manageable exercises and becomes more challenging over time. Treatment may also include practice between appointments, because the learning needs to extend into daily life.
A previous experience with general talk therapy does not necessarily mean someone has received ERP. Likewise, a brief or poorly paced exposure exercise may not represent an adequate course of OCD-focused treatment.
Before describing ERP as unsuccessful, we may ask:
- Was the therapist specifically trained to treat OCD?
- Were exposures connected to the patient’s actual obsessions and compulsions?
- Did treatment address mental rituals, reassurance seeking, and avoidance?
- Was the pace challenging but manageable?
- Was the patient able to practice consistently outside appointments?
- Did another condition interfere with participation?
- Did treatment end because it was ineffective, inaccessible, or too difficult to continue?
These questions are not intended to blame patients. ERP can be demanding, and access to experienced OCD therapists remains uneven. The answers help clarify whether a different format, pace, provider, or level of support may still be useful.
What an Adequate Medication Trial for OCD Involves
Selective serotonin reuptake inhibitors, or SSRIs, are common first-line medications for OCD. Clomipramine, a serotonin reuptake inhibitor in the tricyclic antidepressant class, is another established option.
Medication treatment for OCD often differs from treatment for depression. OCD may require a longer trial and, when medically appropriate, a higher dose before the response can be evaluated fairly.
That does not mean every patient should automatically receive the highest possible dose. Medication decisions must account for age, other prescriptions, medical history, side effects, previous responses, and individual risk.
When we review a past medication trial, we look at:
- Which medication was prescribed
- The highest tolerated dose
- How long it was taken
- Whether doses were missed or interrupted
- Which symptoms improved
- Which symptoms remained
- Whether side effects limited the trial
- Whether ERP was used at the same time
- Whether another diagnosis may have affected the response
A medication that did not help at a low dose over several weeks may not have received an adequate OCD trial. At the same time, patients should not be pressured to continue a medication when the risks or side effects outweigh the likely benefit.
No one should increase, reduce, or discontinue a psychiatric medication without guidance from the prescribing provider.
What We Consider When the First Treatment Is Not Enough
An incomplete response to one SSRI does not mean that all medication options have been exhausted. Depending on the patient, a clinician may consider a different SSRI, clomipramine, a combination with ERP, or an adjunctive medication.
These choices require careful monitoring. Clomipramine has a different side-effect and safety profile from SSRIs. Certain augmentation strategies also carry metabolic, neurological, or other risks that should be weighed against the expected benefit.
Our psychiatric medication management service includes evaluation, prescribing, follow-up, and medication adjustments for OCD and other mental health conditions.
We do not approach medication management as a process of changing prescriptions at random. We review the sequence of previous treatments and try to understand what each one revealed about symptoms, tolerability, and diagnosis.
Some patients use our medication management service independently. Others continue with an outside prescriber while we provide another part of their care. When patients authorize communication, we can coordinate with existing therapists, psychiatrists, and primary care providers.
Why We Reassess the Diagnosis and Symptom Pattern
OCD can coexist with depression, anxiety, PTSD, tic disorders, attention difficulties, eating disorders, or other conditions. It can also be confused with generalized worry, perfectionism, psychosis, trauma-related hypervigilance, or repetitive behaviors that arise for another reason.
Accurate diagnosis matters because treatments that help one condition may not address another.
We want to understand:
- When the symptoms began
- How much time they consume
- Which situations trigger them
- What the patient fears will happen without a compulsion
- Whether insight changes when symptoms are severe
- Which behaviors are compulsions rather than preferences or habits
- Whether depression or another condition is increasing impairment
- Whether intrusive thoughts are unwanted or connected to an intention to act
- How symptoms affect work, school, relationships, sleep, and self-care
OCD themes can vary, but treatment is not determined only by the theme. Contamination OCD, harm OCD, scrupulosity, relationship OCD, checking, counting, and symmetry-related symptoms are all maintained by patterns of obsession, distress, avoidance, and compulsion.
We describe the clinic-specific options we consider on our OCD treatment page, but an individualized evaluation is still necessary before any recommendation is made.
What the Evidence Says About Ketamine for OCD
Researchers have investigated ketamine for OCD partly because ketamine affects NMDA receptors and glutamate signaling. Glutamate is involved in several brain circuits studied in connection with obsessive-compulsive symptoms.
The biological rationale is interesting, but a plausible mechanism is not proof that a treatment works.
A small randomized crossover trial published in 2013 studied one IV ketamine infusion in 15 unmedicated adults with frequent obsessions. Some participants experienced a short-term reduction in symptoms, but the study was too small to establish how consistently ketamine works or which patients are most likely to benefit.
A more recent controlled study examined intramuscular ketamine in 12 adults with severe treatment-resistant OCD, 10 of whom completed the study. It also reported short-term symptom reductions, along with temporary dissociative and cardiovascular effects.
These studies add to the research conversation, but they do not create a mature evidence base. They involved very small groups, different administration routes, limited follow-up, and short-term outcomes. Published reviews have also noted that results across the available studies are mixed and that larger, longer trials are needed.
We do not tell patients that ketamine has been proven to correct the biology driving their OCD. We also do not present it as a replacement for ERP or established medication strategies.
IV ketamine for OCD is an off-label use. It has not been approved specifically as an OCD treatment, individual results vary, and no outcome can be guaranteed. To understand more about how ketamine works at the neurological level, see our overview of how ketamine works in the brain.
How We Evaluate Ketamine Candidacy at Thrive
We do not determine candidacy from a diagnosis or online questionnaire alone.
Our ketamine therapy screening process includes psychiatric and medical evaluations. For a patient with OCD, we review symptom severity, previous ERP, medication history, co-occurring diagnoses, physical health, current prescriptions, substance-use history, and possible safety concerns.
We also want to understand what the patient expects from treatment. Ketamine should not be presented as a way to eliminate every intrusive thought or make uncertainty disappear.
A more responsible conversation focuses on whether treatment may reduce symptom severity enough to support daily functioning and continued engagement with established care. Even if symptoms change, patients may still need ERP, medication management, or other ongoing support.
Candidacy can also depend on whether the condition is stable enough for an altered-state experience. Certain medical or psychiatric concerns may require additional assessment, a change in timing, or a different treatment recommendation.
If ketamine is not appropriate, we explain that honestly. An evaluation is not a commitment to begin treatment.
Where Ketamine-Assisted Psychotherapy May Fit
Ketamine-assisted psychotherapy, or KAP, combines ketamine treatment with therapeutic preparation, support during the medicine experience, and integration afterward.
At Thrive, KAP is an available treatment format. However, evidence for KAP as an OCD-specific intervention is extremely limited.
We cannot say that KAP has been shown to make ERP more effective, create reliable cognitive flexibility, or provide a proven “neuroplastic window” for changing compulsions. Those ideas remain theoretical in relation to OCD and should not be treated as established clinical outcomes.
A patient may still value preparation, therapist presence, and integration as parts of the treatment experience. That preference can be discussed during evaluation, particularly when the patient is already working with an OCD therapist.
Our overview of how ketamine-assisted psychotherapy works explains the general structure of KAP at our clinic.
When OCD is the condition being targeted, KAP should not quietly replace ERP with nonspecific emotional exploration. If a patient is participating in ERP, coordination with the treating therapist can help keep each service’s role clear.
Why Coordination With an OCD Therapist Matters
Ketamine treatment and ERP involve different forms of care.
Our clinical team provides medical and psychiatric evaluation, monitored ketamine treatment when appropriate, and psychiatric medication management. We do not assume that these services replace specialized OCD psychotherapy.
With the patient’s permission, communication with an ERP therapist may help clarify:
- The symptoms currently being targeted
- Compulsions that may not be immediately visible
- Whether reassurance seeking is entering treatment conversations
- How progress is being measured
- What support is appropriate after an infusion
- Whether changes in symptoms affect the ERP plan
- How to respond if distress or avoidance increases
Coordination can also help prevent mixed messages. One provider should not encourage a patient to avoid discomfort while another is helping the patient practice tolerating uncertainty.
We want each part of the treatment plan to support the same overall goals. Our post on how to support someone with OCD offers additional perspective on what thoughtful, coordinated care looks like from those close to the patient.
What Patients Can Expect During an IV Infusion
When IV ketamine is clinically appropriate, the medication is administered through a vein while our team monitors the patient.
Temporary effects may include changes in perception, awareness, the sense of time, or the feeling of connection to the body and surroundings. Some patients experience nausea, dizziness, anxiety, increased blood pressure, or a dreamlike or detached feeling.
We explain preparation requirements, transportation, monitoring, and recovery before the first appointment. Patients must arrange for a responsible adult to drive them home and should follow the post-treatment instructions provided by our team.
Our guide to what happens during a first ketamine infusion provides more detail about the appointment process.
We monitor more than the subjective experience. An infusion can feel emotionally meaningful without producing a measurable reduction in OCD symptoms.
Clinical progress should be evaluated through changes in obsessions, compulsions, avoidance, time consumed by symptoms, distress, and everyday functioning.
Frequently Asked Questions
Does failing one SSRI mean that my OCD is treatment-resistant?
Not necessarily. Before describing OCD as treatment-resistant, a clinician should review the dose, duration, adherence, side effects, diagnosis, and whether ERP was included. A different SSRI, clomipramine, augmentation, or a more specialized course of ERP may still be appropriate.
Do SSRIs always require higher doses for OCD?
OCD often requires higher SSRI doses than depression, but the appropriate dose varies. A prescriber must consider side effects, other medications, medical history, age, and previous response. Patients should never increase a dose on their own.
Does ketamine work immediately for OCD?
Small studies have observed short-term symptom changes after ketamine, but the evidence is too limited to promise an immediate response. Some participants improved, while others did not. Research has not established a dependable response timeline, a standard long-term protocol, or which patients are most likely to benefit.
Is IV ketamine an approved treatment for OCD?
No. IV ketamine for OCD is an off-label use. It may be considered only after an individualized medical and psychiatric evaluation. Patients should receive a clear explanation of the limited evidence, potential risks, alternatives, and uncertainty surrounding long-term outcomes.
Can ketamine replace ERP?
Ketamine has not been established as a replacement for ERP. ERP remains a first-line treatment for OCD. A patient considering ketamine may still benefit from working with an OCD-trained therapist before, during, or after the treatment course.
Can KAP make it easier to complete ERP?
That has not been established. It is possible that some patients may feel more open or flexible after ketamine, but OCD-specific research has not demonstrated that KAP reliably improves ERP participation or outcomes. We discuss this as an unanswered question rather than a promised benefit.
Does Thrive provide medication management for OCD?
Yes. We provide psychiatric medication management for OCD, including evaluation, medication review, prescribing, monitoring, and adjustments when clinically appropriate. Patients may use this service independently or as one part of a coordinated treatment plan.
Do intrusive harm thoughts mean that I want to act on them?
Not necessarily. Harm obsessions in OCD are typically unwanted, distressing, and inconsistent with the person’s intentions or values. A qualified clinician should still assess the experience carefully, especially when it is difficult to distinguish an obsession from an actual urge, plan, or safety risk.
Call or text 988 if you are experiencing suicidal thoughts or an emotional crisis. Call 911 or go to the nearest emergency department if you believe you may act on thoughts of harming yourself or someone else, cannot remain safe, or face an immediate danger.
Key Takeaways
- OCD involves recurring obsessions, compulsions, or both and can significantly disrupt everyday life.
- ERP and serotonin reuptake inhibitors remain established first-line treatments.
- A previous therapy or medication trial should be reviewed for OCD-specific structure, dose, duration, adherence, and tolerability before it is labeled unsuccessful.
- Additional medication strategies may include another SSRI, clomipramine, or carefully selected augmentation.
- Early ketamine studies in OCD have reported short-term symptom reductions, but the trials are very small and the overall evidence remains limited.
- IV ketamine for OCD is an off-label use and is not an established replacement for ERP.
- Evidence for KAP as an OCD-specific treatment is even more limited.
- We complete psychiatric and medical screening before recommending ketamine therapy.
- Medication management, OCD-focused psychotherapy, ketamine evaluation, and provider coordination may each play different roles in an individualized plan.
- No medication should be stopped or changed without guidance from the prescribing provider.
When OCD Still Controls Too Much of Your Life
When ERP or medication has not provided enough relief, it can be tempting to conclude that your OCD is untreatable. Often, the more responsible next step is to examine the treatment history more closely.
At Thrive Center for Health, we review which therapies and medications you have tried, how the trials were structured, what improved, what remained, and whether another diagnosis or health factor may be affecting the response.
Depending on what we learn, the next step may be psychiatric medication management, renewed coordination with an OCD therapist, evaluation for IV ketamine, or another recommendation outside our clinic.
We will not tell you that ketamine is a cure or that it can replace the work of ERP. We will explain the early research, its limitations, the possible risks, and the role treatment may or may not have within a broader plan.
When you are ready to discuss your history and options, you can contact our Grand Rapids team.
About Thrive Center for Health
At Thrive Center for Health in Grand Rapids, Michigan, we care for patients with complex mental health and chronic pain conditions, including people who have not found adequate relief through previous treatment.
We provide IV and IM ketamine therapy, ketamine-assisted psychotherapy, psychiatric medication management, and complementary patient support. Our process emphasizes thorough evaluation, individualized planning, continuous clinical monitoring, and honest communication.
Our clinic includes private treatment rooms and a calm, affirming environment. Our care culture is grounded in being compassionate, approachable, inspiring, dedicated, and authentic.
Thrive Center for Health is located at 847 Parchment Drive SE, Suite 105, Grand Rapids, MI 49546.
Medical Disclaimer
This content is provided for educational purposes only and does not constitute medical advice, diagnosis, or an individualized treatment recommendation. IV ketamine for OCD and other psychiatric conditions is an off-label use and may not be appropriate for every patient. Individual results vary, and no outcome can be guaranteed.
Always consult a qualified healthcare provider before starting, stopping, or changing medication, psychotherapy, or another treatment.
If you are experiencing suicidal thoughts or an emotional crisis, call or text 988. Call 911 or go to the nearest emergency department if there is an immediate danger to you or someone else.
Works Cited
Bandeira, I. D., Lins-Silva, D. H., Cavenaghi, V. B., Dorea-Bandeira, I., & Faria-Guimarães, D. (2022). Ketamine in the treatment of obsessive-compulsive disorder: A systematic review. Harvard Review of Psychiatry, 30(2), 135–145.
Beaglehole, B., Glue, P., Neehoff, S., et al. (2025). Ketamine for treatment-resistant obsessive-compulsive disorder: Double-blind active-controlled crossover study. Journal of Psychopharmacology, 39(1), 23–28.
Foa, E. B., Liebowitz, M. R., Kozak, M. J., et al. (2005). Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. American Journal of Psychiatry, 162(1), 151–161.
Kew, B. M., Porter, R. J., Douglas, K. M., Glue, P., Mentzel, C. L., & Beaglehole, B. (2023). Ketamine and psychotherapy for the treatment of psychiatric disorders: Systematic review. BJPsych Open, 9(3), e79.
National Institute of Mental Health. (2023). Obsessive-compulsive disorder: When unwanted thoughts or repetitive behaviors take over. National Institutes of Health.
Rodriguez, C. I., Kegeles, L. S., Levinson, A., et al. (2013). Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: Proof-of-concept. Neuropsychopharmacology, 38, 2475–2483.
Van Ameringen, M., Fineberg, N. A., Ravindran, A., et al. (2026). Canadian Network for Mood and Anxiety Treatments and International College of Obsessive-Compulsive Spectrum Disorders 2025 international guidelines for the management of patients with obsessive-compulsive disorder. Journal of Psychiatric Research, 199, 404–488.